Stockscreener 앱 받기
1.48
3.50%
0.05
시간 외 거래:
1.53
0.05
+3.38%
전일 마감가:
$1.43
열려 있는:
$1.46
하루 거래량:
432.81K
Relative Volume:
0.76
시가총액:
$41.62M
수익:
$80.97M
순이익/손실:
$-78.31M
주가수익비율:
-0.0997
EPS:
-14.85
순현금흐름:
$-129.56M
1주 성능:
-15.91%
1개월 성능:
-19.13%
6개월 성능:
-23.32%
1년 성능:
-29.19%
1일 변동 폭
$1.455
$1.54
1주일 범위
$1.41
$1.75
52주 변동 폭
$1.355
$4.43
Fortress Biotech Inc Stock (FBIO) Company Profile
명칭
Fortress Biotech Inc
전화
781-652-4500
주소
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
FBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| FBIO | 1.48 | 41.62M | 80.97M | -78.31M | -129.56M | -14.85 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-15 | 재개 | ROTH MKM | Buy |
| 2022-08-04 | 개시 | Ladenburg Thalmann | Buy |
| 2020-10-02 | 개시 | The Benchmark Company | Buy |
| 2019-12-18 | 개시 | B. Riley FBR | Buy |
| 2018-02-28 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-07-11 | 개시 | Rodman & Renshaw | Buy |
| 2017-03-22 | 개시 | JMP Securities | Mkt Outperform |
| 2016-10-03 | 개시 | ROTH Capital | Buy |
모두보기
Fortress Biotech Inc 주식(FBIO)의 최신 뉴스
Fortress Biotech price target lowered to $4 from $5 at Alliance Global Partners - TipRanks
Fortress Biotech price target raised to $26 from $24 at H.C. Wainwright - TipRanks
Fortress Biotech (FRA:CNB1) Total Inventories : €9.00 Mil (As of Jun. 2024) - GuruFocus.com
Fortress Biotech Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Fortress Biotech: Q3 Earnings Snapshot - mySA
Fortress Biotech Inc. (FBIOP) Quarterly 10-Q Report - Quartzy
Fortress Biotech’s Q3 2024 Earnings and FDA Milestone - TipRanks
Fortress Biotech Q3 2024 Earnings: EPS Loss of $0.76 Beats Estimate, Revenue of $14.63M Misses Expectations - GuruFocus.com
Fortress Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
Avenue Therapeutics Reports $3.1M Q3 Loss, Advances Key Clinical Trials Pipeline | ATXI Stock News - StockTitan
Mustang Bio gets extension for Nasdaq compliance By Investing.com - Investing.com South Africa
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewswire
Checkpoint Therapeutics Sets FDA Review Date, Secures $9.2M Funding Boost Amid Q3 Loss | FBIO Stock News - StockTitan
Journey Medical's Mixed Q3: FDA Win for Rosacea Drug Despite Revenue Dip | FBIO Stock News - StockTitan
Mustang Bio gets extension for Nasdaq compliance - Investing.com
Mustang Bio Receives Positive Listing Determination from Nasdaq - The Manila Times
Mustang Bio Secures Critical Nasdaq Extension, Faces January 2025 Deadline for $1 Compliance | MBIO Stock News - StockTitan
Where are the Opportunities in (FBIOP) - Stock Traders Daily
Mustang Bio gains FDA Orphan Drug Status for glioma treatment - Investing.com India
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for - GlobeNewswire
Mustang Bio gains FDA Orphan Drug Status for glioma treatment By Investing.com - Investing.com UK
How To Trade (FBIOP) - Stock Traders Daily
Fortress Biotech Insiders Placed Bullish Bets Worth US$4.49m - Yahoo Finance
Biotech Stocks Facing FDA Decision In November 2024 - RTTNews
Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 36% But Its Business Still Trails The Industry - Simply Wall St
Mustang Bio, Inc. Appoints David Jin as A Member of the Board - Marketscreener.com
Highbridge Capital Management's Strategic Acquisition of Fortress Biotech Shares - Yahoo Finance
Highbridge Capital Management's Strategic Acquisition of Fortres - GuruFocus.com
Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference - GlobeNewswire
Mustang Bio secures $4 million from warrant exercises - Investing.com India
Mustang Bio secures $4 million from warrant exercises By Investing.com - Investing.com South Africa
Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds - The Manila Times
Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit - The Manila Times
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit - GlobeNewswire
Analysts review Fortress Biotech Inc’s rating - Knox Daily
Was there any good news for Fortress Biotech Inc (FBIO) stock in the last session? - US Post News
PRESIDENT, CEO & CHAIRMAN ROSENWALD LINDSAY A MD acquire 763,359 shares of Fortress Biotech Inc [FBIO] - Knox Daily
Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - GlobeNewswire
Fortress Biotech Inc (FBIO) expanding its growth trajectory ahead - SETE News
Nantahala Capital Management LLC Sells 125,000 Shares of Fortress Biotech, Inc. (NASDAQ:FBIO) - Defense World
PVG Asset Management Corp Invests $266,000 in Fortress Biotech, Inc. (NASDAQ:FBIO) - Defense World
Fortress Biotech Inc (FBIO) receives a Buy rating from ROTH MKM - Knox Daily
Fortress Biotech Inc (FBIO)’s results reveal risk - US Post News
Fortress Biotech Inc (FBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):